About NOXXON
NOXXON’s oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor micro-environment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 has delivered top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients in 2018.
| • Download the initiation report on NOXXON by Aurgalys |
| ➥ See latest updates from Aurgalys here |
Press ReleaseBerlin, Germany
2018, December 14 12:30 p.m. NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients 2018, December 13 8:00 p.m. NOXXON announces trading halt on Euronext Growth Paris ahead of trial data publication at the ESMO Immuno-Oncology Congress 2018, December 10 8:00 a.m. NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at ESMO immuno-oncology congress on December 13-16, 2018 |
EventsAram Mangasarian, Jarl Ulf Jungnelius, Dirk Eulberg Aram Mangasarian, Jarl Ulf Jungnelius Aram Mangasarian, Jarl Ulf Jungnelius |